In a study published by Nature and sponsored by The Cancer
Genome Atlas Network distinguished between four different types of cancer. The
study analyzed the tumors from 825 patients making it the largest breast cancer
genomics project.
Scientists were primarily researching
what is thought to be the most common type of breast cancer that begins in the
milk duct. They were analyzing tumors that had not yet metastasized, and from
their sample size they found dramatic differences among the tumors. They found
a particular type of breast cancer in which the tumor cells more closely
resemble basal cells. This discovery changes the way that scientist attempt to
treat this type of cancer. Rather than treat basal-like cancers with
anthracyclines, this study provides evidence that it might be more efficient to
use treatments for ovarian cancer—these treatments are also gentler and are not
associated with heightened risk for heart damage and leukemia.
The study
also found two other types of breast cancer in the luminal cells in the milk
ducts. One kind is associated with a good prognosis and suggests that hormonal
therapy is sufficiently effective, whereas those with the other type of luminal
cancer, Luminal B might benefit from chemotherapy in addition. The research
also found that certain genetic aberations were so strongly associated to each
of the different types of luminal subtypes that there may be a causational
relationship.
The last
type of breast cancer that researchers identified is HER2-enriched. There is a
drug to block the gene, Herceptin, leading to a very effective targeted
therapy. However, Herceptin is associated with risks so knowing if one has
HER2-enriched breast cancer helps doctors tailor treatments to the individual.
To
conclude, by specifying the type of breast cancer a person has doctors are now
able to better treat the cancer rather than the entire body system. This will
be to the benefit of the patient who wont be victim of a chemical cocktail but
instead of a targeted treatment.
No comments:
Post a Comment